ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. / Laenkholm, Anne-Vibeke; Knoop, Ann; Ejlertsen, Bent; Rudbeck, Tine; Jensen, Maj-Britt; Müller, Sven; Lykkesfeldt, Anne Elisabeth; Rasmussen, Birgitte Bruun; Nielsen, Kirsten Vang.
In: Molecular Oncology, Vol. 6, No. 4, 08.2012, p. 428-36.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry
AU - Laenkholm, Anne-Vibeke
AU - Knoop, Ann
AU - Ejlertsen, Bent
AU - Rudbeck, Tine
AU - Jensen, Maj-Britt
AU - Müller, Sven
AU - Lykkesfeldt, Anne Elisabeth
AU - Rasmussen, Birgitte Bruun
AU - Nielsen, Kirsten Vang
N1 - Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
PY - 2012/8
Y1 - 2012/8
N2 - The Estrogen Receptor (ER) is an established predictive marker for the selection of adjuvant endocrine treatment in early breast cancer. During the 1990s Immunohistochemistry (IHC) replaced cytosol based assays for determination of ER status. This study examined the association between ER protein level determined by two different methods and ESR1 gene copy number. From 289 primary high-risk breast cancer patients, randomized in the Danish Breast Cancer Cooperative Group (DBCG) 77C trial, results from cytosolic ER levels were available from ligand binding assays. Archival tumor tissue was retrieved from 257 patients. ESR1/CEN-6 ratio was analyzed successfully by Fluorescence In Situ Hybridization (FISH) in 220 (86%) patients. ESR1 amplification (ESR1/CEN-6 ≥ 2.00) was observed in 23% of the patients and ESR1 deletion (ESR1/CEN-6 < 0.80) was observed in 32%. Further, we identified ESR1 gain (ratio ESR1/CEN-6 from 1.30 to 1.99) in 19% of the patients. A positive correlation of ESR1 FISH with both ER-cytosol and ER IHC was found (p < 0.0001). Amplification and gain of the ESR1 gene are associated with higher ER protein content measured by ligand binding assay and a more intense nuclear staining by IHC compared to tumors with normal ESR1 gene status. Major variations in ER measured by ligand binding assay and IHC are observed within all ESR1 copy number subgroups and other mechanisms than gene copy number seem to contribute to the ER protein content in the tumors.
AB - The Estrogen Receptor (ER) is an established predictive marker for the selection of adjuvant endocrine treatment in early breast cancer. During the 1990s Immunohistochemistry (IHC) replaced cytosol based assays for determination of ER status. This study examined the association between ER protein level determined by two different methods and ESR1 gene copy number. From 289 primary high-risk breast cancer patients, randomized in the Danish Breast Cancer Cooperative Group (DBCG) 77C trial, results from cytosolic ER levels were available from ligand binding assays. Archival tumor tissue was retrieved from 257 patients. ESR1/CEN-6 ratio was analyzed successfully by Fluorescence In Situ Hybridization (FISH) in 220 (86%) patients. ESR1 amplification (ESR1/CEN-6 ≥ 2.00) was observed in 23% of the patients and ESR1 deletion (ESR1/CEN-6 < 0.80) was observed in 32%. Further, we identified ESR1 gain (ratio ESR1/CEN-6 from 1.30 to 1.99) in 19% of the patients. A positive correlation of ESR1 FISH with both ER-cytosol and ER IHC was found (p < 0.0001). Amplification and gain of the ESR1 gene are associated with higher ER protein content measured by ligand binding assay and a more intense nuclear staining by IHC compared to tumors with normal ESR1 gene status. Major variations in ER measured by ligand binding assay and IHC are observed within all ESR1 copy number subgroups and other mechanisms than gene copy number seem to contribute to the ER protein content in the tumors.
KW - Biological Assay/methods
KW - Breast Neoplasms/genetics
KW - Charcoal
KW - Estrogen Receptor alpha/genetics
KW - Female
KW - Gene Dosage/genetics
KW - Genes, Neoplasm/genetics
KW - Humans
KW - Immunohistochemistry/methods
KW - In Situ Hybridization, Fluorescence
KW - Ligands
KW - Neoplasm Invasiveness
KW - Ploidies
U2 - 10.1016/j.molonc.2012.04.003
DO - 10.1016/j.molonc.2012.04.003
M3 - Journal article
C2 - 22626971
VL - 6
SP - 428
EP - 436
JO - Molecular Oncology
JF - Molecular Oncology
SN - 1574-7891
IS - 4
ER -
ID: 259931487